<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4288705</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P60</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P60</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Slingluff</surname><given-names>Craig L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Petroni</surname><given-names>Gina R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Olson</surname><given-names>Walter C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Chianese-bullock</surname><given-names>Kimberly A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Smith</surname><given-names>Kelly T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Smolkin</surname><given-names>Mark E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Galeassi</surname><given-names>Nadedja</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Grosh</surname><given-names>William</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Weiss</surname><given-names>Geoffrey</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Scott</surname><given-names>Kristy</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Hornillo</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Virginia, Charlottesville, USA</aff><aff id="I2"><label>2</label>Glaxo Smith Kline, Belgium</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P60</fpage><lpage>P60</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Slingluff et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Slingluff et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P60"/><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The recMAGE-A3 protein has been administered intramuscularly (IM) with immunostimulant AS15 as an experimental immunotherapeutic. AS15 contains 3-O-desacyl-4'-monophosphoryl lipid A (MPL), QS-21, CpG 7909 and liposome. This MAGE-A3/AS15 immunotherapeutic has not been studied for intradermal (ID) or subcutaneous (SC) use. A clinical trial (NCT01425749) was initiated to test the hypotheses that ID/SQ administration is safe and may induce CD4<sup>+ </sup>and CD8<sup>+ </sup>T cell responses to MAGE-A3.</p></sec><sec sec-type="methods"><title>Patients and methods</title><p>Twenty-five eligible patients with resected stage IIB-IV MAGE-A3<sup>+ </sup>melanoma were randomized to 2 arms, treated with MAGE-A3/AS15 Immunotherapeutic IM (Arm A, n = 13) or ID/SC (Arm B, n = 12). Adverse events (CTCAE 4) were recorded. Antibody (Ab) responses to MAGE-A3 protein were assessed by ELISA assay. T cell responses were assessed by flow cytometry after intracellular cytokine staining (ICS) for multifunctional CD4<sup>+ </sup>and CD8<sup>+ </sup>responses to overlapping MAGE-A3 peptides, assaying lymphocytes from peripheral blood (PBMC) and sentinel immunized node (SIN), after one <italic>in vitro </italic>stimulation.</p></sec><sec sec-type="results"><title>Results</title><p>In both arms, the recMAGE-A3/AS15 immunotherapeutic was well-tolerated, with only one grade 3 treatment-related adverse event (hyperglycemia, Arm B), and no grade 4 or 5 events. Grade 2 injection site reactions were observed in 10 patients in Arm A and 7 in Arm B (P &#x0003e; 0.3). Ab responses were detected in all patients, most with high titers persisting at least 6 months, without difference between arms. Preliminary T cell data are that multifunctional (IFNg and TNF&#x003b1;) CD4<sup>+ </sup>T cell responses to MAGE-A3 were detected in 64% of patients (54% A; 75% B; Table <xref ref-type="table" rid="T1">1</xref>). Multifunctional CD8<sup>+ </sup>T cell responses were evident in 20% of patients (8% A, 33% B). CD4<sup>+ </sup>responses were higher magnitude in SIN than in PBMC.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Multifunctional (IFNg and TNF&#x003b1;) T cell responses to MAGE-A3</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="3">% of CD4+ T cells</th><th align="center" colspan="3">% of CD8+ T cells</th></tr></thead><tbody><tr><td/><td align="center" colspan="3">(90% CI)</td><td align="center" colspan="3">(90% CI)</td></tr><tr><td/><td align="center">SIN</td><td align="center">PBMC</td><td align="center">Either</td><td align="center">SIN</td><td align="center">PBMC</td><td align="center">Either</td></tr><tr><td align="center">Arm A</td><td align="center">31%</td><td align="center">31%</td><td align="center">54%</td><td align="center">0%</td><td align="center">8%</td><td align="center">8%</td></tr><tr><td/><td align="center">(11, 58)</td><td align="center">(11, 58)</td><td align="center">(29, 78)</td><td align="center">(0, 21)</td><td align="center">(0, 32)</td><td align="center">(0, 32)</td></tr><tr><td align="center">Arm B</td><td align="center">64%</td><td align="center">50%</td><td align="center">75%</td><td align="center">18%</td><td align="center">25%</td><td align="center">33%</td></tr><tr><td/><td align="center">(35, 86)</td><td align="center">(25, 75)</td><td align="center">(47, 93)</td><td align="center">(3, 47)</td><td align="center">(7, 53)</td><td align="center">(12, 61)</td></tr><tr><td align="center">Total</td><td align="center">46%</td><td align="center">40%</td><td align="center">64%</td><td align="center">8%</td><td align="center">16%</td><td align="center">20%</td></tr><tr><td/><td align="center">(28, 64)</td><td align="center">(24, 58)</td><td align="center">(46, 80)</td><td align="center">(2, 24)</td><td align="center">(6, 33)</td><td align="center">(8, 38)</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Safety profiles were comparable for ID/SC and IM administration of the MAGE-A3/AS15 immunotherapeutic, which induced high-titer Ab, multifunctional CD4<sup>+ </sup>Th1 responses, and CD8<sup>+ </sup>responses when administered by either route. Immune responses were more readily detected in the SIN than in PBMC. These pilot data support further investigation of ID/SC immunization with antigen plus AS15 to support Th1 CD4<sup>+ </sup>responses and CD8<sup>+ </sup>responses. Production of Th1 cytokines IFNg and TNF&#x003b1; suggests the induced CD4<sup>+ </sup>responses may support CD8<sup>+ </sup>T cells. Other forms of antigen (e.g.: long peptides) may further support induction of CD8<sup>+ </sup>T cell responses in combination with AS15.</p><p>Funding source: GlaxoSmithKline Biologicals SA</p></sec></body></article>